Shire Pharmaceuticals
About Shire Pharmaceuticals
There’s a simple purpose that sits at the heart of our business: to enable people with life-altering conditions to lead better lives. This means we focus on developing treatments for conditions where the impact of our medicines can make an immediate and tangible difference for patients.
Our growth strategy is to focus on developing and marketing innovative specialty medicines for symptomatic conditions to meet significant unmet patient needs. Our two strategic priorities are to drive optimum performance of our existing products, enabling access to these medicines for patients today; and building our pipeline through research and development (R&D) and business development (BD), delivering access in the future for patients We are always looking for talented people to join the Shire team.
To learn more about Shire, visit www.shire.com.
For more information on career opportunities with Shire, please visit: www.TimeToBeBrave.com .
Shire. To be as brave as the people we help.
367 articles about Shire Pharmaceuticals
-
Noven Pharmaceuticals Inc. Confirms Shire plc's Withdrawal of European Marketing Application for Daytrana
3/16/2009
-
Shire plc Pays 55 Million Euros for UCB, Inc.'s Equasym
2/20/2009
-
Shire plc Announces Opening of Office in Japan
2/20/2009
-
Shire Pharmaceuticals Delivers Excellent Growth for the Year, With the new Product Portfolio Achieving Sales of $1 Billion
2/19/2009
-
Shire plc Full Year 2008 Results Date Notification - 19 February 2008
2/9/2009
-
Barr Laboratories, Mylan Inc. Plan Generics of Shire plc's Fosrenol Drug
2/9/2009
-
Shire plc Change to Director's Details
2/6/2009
-
Shire Pharmaceuticals Investor Seminar
11/18/2008
-
Shire plc Release: Confirmation of HGT Business Day - 18th November 2008
11/12/2008
-
Shire plc's New Product Portfolio Delivers Strong Quarterly Performance
10/29/2008
-
Shire Limited Results of the Annual General Meeting Held on September 24, 2008
9/24/2008
-
Shire Limited's VYVANSE(R) Now Available in U.S. Pharmacies Nationwide
8/26/2008
-
Jerini AG's Management and Supervisory Boards Recommend That Jerini Shareholders Accept Shire Limited's Takeover Offer
8/25/2008
-
Wolf Greenfield Wins Three More Years of Patent Protection for Shire Pharmaceuticals' ELAPRASE
8/18/2008
-
Shire Limited Announces Holding of 81% in Jerini AG and Publication of Offer Document
8/13/2008
-
Shire Limited Delivers Strong Quarter
7/31/2008
-
Tatjana May Appointed Chair of Shire Limited's Corporate Responsibility Committee
7/29/2008
-
Shire Limited Announces Robin Buchanan to Step Down as Non-Executive Director on Completion of Term of Office
7/21/2008
-
Shire Limited Second Quarter 2008 Results Date Notification - 31 July 2008
7/7/2008
-
Shire Limited to Buy German Biotech Jerini AG for $518 Million
7/3/2008